OncoSec Medical to Present at Prominent Scientific and Investment Conferences in May
SAN DIEGO, May 4, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that leadership members will present at several high-profile events in May, including: PEGS - The Essential Protein Engineering Summit, 2015 Marcum MicroCap Conference, and Sachs Immuno-Oncology: Business Development & Licensing (BD&L) and Investment Forum.
PEGS – The Essential Protein Engineering Summit
Robert H. Pierce, MD, Chief Scientific Officer, will present a lecture entitled: "Intratumoral Gene Therapy with IL-12 to Enhance Responses to Immune 'Checkpoint' Therapy" at PEGS - The Essential Protein Engineering Summit today, May 4 at 1:55 PM ET at the Seaport World Trade Center in Boston. Dr. Pierce will discuss the ability of intratumoral electroporation of IL-12 to augment immunogenicity, drive tumor infiltrating lymphocyte (TIL) response, and enhance responses to immune "checkpoint" therapies.
The PEGS Summit is the premier event for antibody and protein science research and the biologics industry with more than 1,800 participants in attendance from over 30 countries. During the conference, attendees will share insights and best practices with colleagues, discover industry trends, and find solutions to current health challenges. For more information, please visit: http://www.pegsummit.com/.
2015 Marcum MicroCap Conference
Punit Dhillon, President and CEO, will present a corporate overview at the 2015 Marcum MicroCap Conference on May 27 at 1:00 PM ET at the Grand Hyatt New York in New York City. To view and listen to the live webcast, please access the following link at the time of the presentation: http://wsw.com/webca st/marcum3/oncs. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.
The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from various industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of these companies. For more information, please visit: http://www.marcumllp.com/MicroCap/index.html.
Sachs Immuno-Oncology: BD&L and Investment Forum
Mr. Dhillon will also present a corporate overview at the Sachs Immuno-Oncology: BD&L and Investment Forum on May 29 at 4:30 PM CT at the Hyatt Chicago Magnificent Mile in Chicago.
The Sachs Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharmaceuticals, and biotechnology companies to facilitate partnering and funding/investment. The conference expects approximately 200 delegates and 30 presentations from listed and private biotechnology companies. For more information, please visit: http://www.sachsforum.com/sio15/index.html.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse™ for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse™ in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Inc.